MBL received MHLW approval for its AmoyDx® PIK3CA Mutation Detection Kit

Tokyo, Japan - March 23, 2026 - Medical ＆ Biological Laboratories Co., Ltd. (CEO: Hiroki Ito), a group company of Tokuyama Corporation (President: Hiroshi Yokota), Amoy Diagnostics Co., Ltd. (Founder and Chairman: Li-Mou Zheng) and Precision Medicine Asia Co., Ltd. (President and CEO: Tatsuya Ikeda) today announced that MBL received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) on March 5, 2026 for the AmoyDx® PIK3CA Mutation Detection Kit in Japan. The approval in Japan marks an important milestone achieved through the close collaboration of MBL, AmoyDx and PREMIA. Read the full story here:

MHLW Approval for AmoyDx PIK3CA Mutation Detection Kit.pdf

Download PDF • 149KB